ArticleAntimicrobial agents and chemotherapy2012
Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Isolation, characterization and genomic analysis of a novel lytic bacteriophage EcoPhCCP1, capable of infecting multiple strains of multidrug-resistantThe Journal of general virology · 2026Article
- Clinical and Demographic Features Associated with the Isolation of Ceftriaxone-Resistant Enterobacteriaceae in a Private Hospital in Kingston, Jamaica.The American journal of tropical medicine and hygiene · 2025Article
- Navigating an evolving microbial landscape: emerging antimicrobial resistance trends and precision stewardship in Tianjin tertiary hospitals (2021-2023).Frontiers in cellular and infection microbiology · 2025Article
- Appropriateness of Empiric Initiation of Meropenem in the Intensive Care Unit as Determined by Internal Medicine Residents.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Systematic Review of Plasmid AmpC Type Resistances inMicroorganisms · 2022Article
- Epidemiology of extended-spectrum beta-lactamase producing Enterobacteriaceae in Qatar: A 3-year hospital-based study.Frontiers in antibiotics · 2022Article
- Antibacterial Potential by Rupture Membrane and Antioxidant Capacity of Purified Phenolic Fractions ofAntibiotics (Basel, Switzerland) · 2021Article
- Clinical and demographic features associated with infections with extended-spectrum beta-lactamase-producingAntimicrobial stewardship & healthcare epidemiology : ASHE · 2021Article
- Molecular Epidemiology of Ceftriaxone Non-Susceptible Enterobacterales Isolates in an Academic Medical Center in the United States.Open forum infectious diseases · 2019Article
- Prevalence of Cefepime-ResistantIranian journal of public health · 2019Review
- Prevalence and Antimicrobial Susceptibility Patterns of ESBL, AmpC and Carbapenemase-producingIranian journal of pharmaceutical research : IJPR · 2018Article
- Alarming levels of antimicrobial resistance among sepsis patients admitted to ICU in a tertiary care hospital in India - a case control retrospective study.Antimicrobial resistance and infection control · 2018Article
- Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2017Review
- Characterization of a Novel IncHI2 Plasmid Carrying Tandem Copies of blaCTX-M-2 in a fosA6-Harboring Escherichia coli Sequence Type 410 Strain.Antimicrobial agents and chemotherapy · 2016Article
- The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.Leukemia & lymphoma · 2016Review
- Review
- Faropenem disks for screening of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.Journal of clinical microbiology · 2014Article
- Phenotypic detection of plasmid-acquired AmpC in Escherichia coli--evaluation of screening criteria and performance of two commercial methods for the phenotypic confirmation of AmpC production.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013Article
- Higher Prevalence of Klebsiella pneumoniae Extended-Spectrum β-Lactamase in Patients on Renal Replacement Therapy.Journal of Korean medical science · 2013Article
- Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
We investigated the clinical and microbiologic features of 300 cases of cephalosporin-resistant Escherichia coli producing extended-spectrum β-lactamase (ESBL) or plasmid-mediated AmpC β-lactamase (pAmpC) at three medical centers in the United States. Solid-organ malignancy, connective tissue disease, and a recent history of surgery were more common among pAmpC-producing cases (n = 49), whereas urinary catheter at enrollment, diabetes, and hospitalization in the past year were more common among ESBL-producing cases (n = 233). The factors independently associated with clinical outcome were the following: the presence of cardiovascular disease (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.29 to 6.43), intra-abdominal infection (OR, 6.35; 95% CI, 1.51 to 26.7), other or multiples sources of infection (OR, 8.12; 95% CI, 2.3 to 28.6), age of 65 years or greater (OR, 0.43; 95% CI, 0.2 to 0.95), favorable baseline health status (OR, 0.39; 95% CI, 0.16 to 0.95), and appropriate empirical antimicrobial therapy given in the first 72 h (OR, 0.42; 95% CI, 0.20 to 0.88). β-Lactamase genes responsible for cephalosporin resistance were identified in 291 cases. CTX-M-type ESBLs accounted for 72.0%. Of those, 88.0% were CTX-M-15. The next most common type was CMY-type pAmpC (16.7%), followed by SHV- and TEM-type ESBLs (6.3 and 1.3%, respectively). Seven cases (2.3%) had KPC-type β-lactamase. Ertapenem, imipenem, meropenem, doripenem, piperacillin-tazobactam, amikacin, nitrofurantoin, and tigecycline were highly active, with greater than 90% of the isolates being susceptible. Cefepime was less active, with only 74.2% being susceptible due to the predominance of CTX-M-15. These findings have implications in the selection of appropriate empirical therapy when infection due to cephalosporin-resistant E. coli is suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.